from FibroGen, Inc.. Feb. 19 CI Perspective Therapeutics Appoints Juan Graham as CFO; Shares Fall Jan. 06 MT FibroGen : Appoints David DeLucia as Chief Financial Officer Form 8 K Dec. 16 PU FibroGen Names David DeLucia CFO Dec. 16 MT FibroGen Appoints David DeLucia as ...
Get the latest FibroGen Inc (FGEN) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.
SEC Filings Financial Information Shareholder Services Investor FAQs FibroGen Inc. NASDAQ: FGEN $0.28 -0.0143 (-4.86%)Volume: 1,697,307Apr 04, 2025 4:00 PM EDT Minimum 15 minutes delayed. Source: LSEG Investor and Media Contact Investors: ...
The Investor Relations website contains information about FibroGen, Inc.'s business for stockholders, potential investors, and financial analysts.
FibroGen, Inc. (FGEN) Frequently Asked Questions People Also Follow SymbolLast PriceChange KPTIKaryopharm Therapeutics Inc. 0.62 Post. 0.62 1.13% 0.55% AKBAAkebia Therapeutics, Inc. 2.13 Post. 2.13 -0.47% -0.01% ATRAAtara Biotherapeutics, Inc. ...
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2023 and provided an update on the company’s recent developments.“We look forward to reporting topline data from four pivotal phase 3 trials ...
旧金山,2025年3月3日(全球新闻通讯)-- FibroGen, Inc.(纳斯达克:FGEN)将在2024年3月17日周一市场收盘后宣布2024年第四季度和全年财务业绩。 GlobeNewswire05:45 快讯| FibroGen Inc - 签署了与不时出售普通股相关的ATM股权发行销售协议 快讯02/25 06:22 FibroGen公司(纳斯达克:FGEN)股票暴涨46%,尽管其价格...
旧金山,2025年3月3日(全球新闻通讯)-- FibroGen, Inc.(纳斯达克:FGEN)将在2024年3月17日周一市场收盘后宣布2024年第四季度和全年财务业绩。 GlobeNewswire03/04 05:45 快讯| FibroGen Inc - 签署了与不时出售普通股相关的ATM股权发行销售协议 快讯02/25 06:22 FibroGen公司(纳斯达克:FGEN)股票暴涨46%,尽管...
Quotes News & Analysis Dividend History Historical Quotes Historical NOCP Financials Earnings P/E & PEG Ratios More Portfolio Watchlist BreadcrumbFGEN Pre-Market FibroGen, Inc Common Stock (FGEN) Pre-Market Data last updated Apr 11, 2025 09:30 AM ET. This page will resume updating...
FibroGen, Inc.(FGEN)宣布,美国食品和药物管理局(FDA)已批准其抗CTGF抗体pamrevlumab用于治疗杜氏肌营养不良症(DMD)患者的快速通道。这一命名基于非门诊DMD患者单臂II期临床数据进行回顾数据。Pamrevlumab目前正在两个治疗DMD的III期临床试验中进行评估。